2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Lactate Dehydrogenase
  5. Lactate Dehydrogenase Inhibitor

Lactate Dehydrogenase Inhibitor

Lactate Dehydrogenase Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-W013032A
    Oxamic acid sodium
    		Inhibitor 99.72%
    Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.
  • HY-100681
    GSK2837808A
    		Inhibitor ≥99.0%
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
  • HY-16214
    FX-11
    		Inhibitor 99.21%
    FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.
  • HY-100742A
    (R)-GNE-140
    		Inhibitor 99.73%
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
  • HY-W040118
    Galloflavin
    		Inhibitor 99.36%
    Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated Kis for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production.
  • HY-W013032
    Oxamic acid
    		Inhibitor 99.98%
    Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis.
  • HY-168172
    LDH-IN-3
    		Inhibitor
    LDH-IN-3 (compound E38) is an inhibitor of LDH, promising protective agent for ischemic nerve damage in the eye and brain. LDH-IN-3 acts its function via HO-1/SIRT1 pathway..
  • HY-147216
    AXKO-0046
    		Inhibitor 99.64%
    AXKO-0046, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor.AXKO-0046 has LDHB inhibitory activity with an EC50 value of 42 nM.AXKO-0046 can be used for the research of cancer metabolism.
  • HY-139319
    LDHA-IN-3
    		Inhibitor 99.88%
    LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer.
  • HY-18968
    LDHA-IN-4
    		Inhibitor 98.06%
    AZ-33 is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 0.5 μM and a Kd of 0.093 μM.
  • HY-100742
    GNE-140 racemate
    		Inhibitor 99.38%
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor.
  • HY-111108
    LDH-IN-1
    		Inhibitor 99.86%
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
  • HY-147216A
    AXKO-0046 dihydrochloride
    		Inhibitor 99.68%
    AXKO-0046 dihydrochloride, indole derivative, is an uncompetitive Lactate dehydrogenase B (LDHB) selective inhibitor. AXKO-0046 dihydrochloride has LDHB inhibitory activity with an EC50 value of 42 nM. AXKO-0046 dihydrochloride can be used for the research of cancer metabolism.
  • HY-124309
    NHI-2
    		Inhibitor 99.30%
    NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.
  • HY-N0743
    Senkyunolide A
    		Inhibitor 99.92%
    Senkyunolide A is a phthalein compound. Senkyunolide A inhibits the proliferation of tumor cells and has anticancer activity. Senkyunolide A inhibits the progression of osteoarthritis through the NLRP3 signaling pathway. Senkyunolide A protects nerve cells from Corticosterone (HY-B1618) -induced apoptosis by regulating protein phosphatase 2A and α-synuclein signaling pathways. Senkyunolide A inhibits the expression of CD137, a diagnostic biomarker for atherosclerosis.
  • HY-W040073
    Nifurtimox
    		Inhibitor 99.65%
    Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
  • HY-132606A
    Nedosiran sodium
    		Inhibitor
    Nedosiran sodium is a GalNAc-dsRNA conjugate designed to inhibit production of the hepatic lactate dehydrogenase (LDH) enzyme.
  • HY-N2498
    Glomeratose A
    		Inhibitor 99.89%
    Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia.
  • HY-N2177
    3-Dehydrotrametenolic acid
    		Inhibitor 99.86%
    3-​Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-​Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-​Dehydrotrametenolic acid induces apoptosis and has anticancer activity.
  • HY-156683
    CHK-336
    		Inhibitor 98.05%
    CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria.